Ravi Iyengar, PhD
Dr. Iyengar's expertise is in the systems biology of cellular regulatory networks. He uses a combination of experimental and computational approaches to study how systems-level regulation of molecular interactions propagate across scales of organization to produce organ-level physiology and pathophysiology. His group is developing large- scale network models of drug-target interactions within the human interactome and using these systems to develop classifiers that are used to explain adverse events in the FDA adverse event database. He is the Dorothy H and Lewis Rosenstiel Professor in the Department of Pharmacology and Systems Therapeutics and Director of the Systems Biology Center New York at the Icahn School of Medicine at Mount Sinai.